Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. (2022)
Attributed to:
The Oxford Single Cell Biology Consortium
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.2217/fon-2022-0484
PubMed Identifier: 35950489
Publication URI: http://europepmc.org/abstract/MED/35950489
Type: Journal Article/Review
Volume: 18
Parent Publication: Future oncology (London, England)
Issue: 27
ISSN: 1479-6694